Guidelines Flashcards
(254 cards)
What is the criteria for Level 1 Evidence?
Meta-analysis with narrow confidence intervals and/or 2 or more RCTs with adequate sample size, preferably placebo controlled
What is the criteria for Level 2 Evidence?
Meta-analysis with wide confidence intervals and/or 1 or more RCTs with adequate sample size
What is the criteria for Level 3 Evidence?
Small-sample RCTs or nonrandomized, controlled prospective studies or case series or high-quality retrospective studies
What is the criteria for Level 4 Evidence?
Expert opinion/consensus
According to CANMAT, how does a recommendation become first line?
Level 1 or Level 2 Evidence, plus clinical support
According to CANMAT, how does a recommendation become second line?
Level 3 Evidence or higher, plus clinical support
According to CANMAT, how does a recommendation become third line?
Level 4 Evidence or higher, plus clinical support
According to CANMAT Depression Guidelines (2016), what medications are first line?
(Long answer)
Remember - SSRIs, SNRIs, NDRI, “MMAV”
- All SSRIs
- Escitalopram
- Citalopram
- Fluoxetine
- Fluvoxamine
- Paroxetine
- Sertraline
- All SNRIs (minus Levomilnacipran)
- Duloxetine
- Venlafaxine
- Desvenlafaxine
- Milnacipran
- NDRI
- Bupropion
- a2-Adrenergic agonist; 5-HT2 antagonist
- Mirtazapine
- Mianserin
- 2 Others
- Agomelatine (MT1 and MT2 agonist; 5-HT2 antagonist)
- Vortioxetine (Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B partial
agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist)
According to CANMAT Depression Guidelines (2016), what medications are second line?
Remember: TCAs, Quetiapine, LevoM, MAOS, and “dones”
- TCAs
- Amitriptyline, domipramine, desipramine, nortriptyline, etc
- Quetiapine
- Levomilnacipran (SNRI)
- Moclobemide (Reversible Inhibitor of MAO-A)
- Selegeline (Irreversible Inhibitor of MAO-B)
- Trazodone (Serotonin reuptake inhibitor; 5-HT2 antagonist)
- Vilazodone (Serotonin reuptake inhibitor; 5-HT1A partial agonist)
According to CANMAT Depression Guidelines (2016), what medications are third line?
- Irreversible MAOs
- Phenelzine
- Tranylcypromine
- Reboxetine (Noradrenaline reuptake inhibitor)
According to CANMAT, what factors should you consider in selecting an antidepressant?
- Patient Factors
- Clinical Features
- Comorbid Conditions
- Response and Side Effects during previous trials
- Patient Preference
- Medication Factors
- Comparative efficacy
- Side Effects /Comparative Tolerabilty
- Potential Interactions
- Ease of use
- Cost and availability
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with anxious distress?
- Use antidepressant with efficacy in GAD
- No difference between SSRI, SNRI, Bupropion
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with catatonia?
Benzodiazepenes
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with melancholic features?
No antidepressants have demonstrated efficacy
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with atypical features?
No antidepressants showed superiority
(Older studies found MAOs >TCAs)
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with psychotic features?
Use antidepressant and antipsychotic co-treatment
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with mixed features?
Lurasidone
Ziprasidone
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with seasonal pattern?
No antidepressants have demonstrated superiority
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with cognitive dysfunction?
Vortioxetine (level 1)
SSRIs
Bupropion
Duloxetine
Moclobemide
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with sleep disturbance?
Agomelatine
Mirtazpine
Trazodone
Quetiapine
(Weigh against potential for side effects)
According to CANMAT Depression Guidelines (2016), what are the reccommendations for MDD with somatic symptoms?
Pain
- Duloxetine - Level 1
- Other SNRIs - Level 2
Fatigue
- Bupropion - Level 1
- SSRIs - Level 2
Low Energy
- Duloxetine - Level 2
What are risk factors to consider longer term (2 years or longer) maintenance treatment with antidepressants?
- Frequent, recurrent episodes
- Severe episodes (psychosis, severe impairment, suicidality)
- Chronic episodes
- Presence of comorbid psychiatric or other medical conditions
- Presence of residual symptoms
- Difficult-to-treat episodes
After you have selected and initiated a first line antidepressant, how long do you wait to determine whether there is early improvement?
2-4 weeks
You have started an antidepressant, and there is early improvement after 2-4 weeks. What do you do next?
Keep patient on treatment for 6-8 weeks, then reassess

